CARE for Blood Cancer Act of 2026
Key claim: The House has introduced the CARE for Blood Cancer Act of 2026 and referred it to the Energy and Commerce Committee.
Abstract
(HR10858 · 119th Congress) Latest action (2026-10-22): Referred to the House Committee on Energy and Commerce.
Why this matters
Blood cancer care touches Medicare coverage, drug access, and clinical trial pathways, so a dedicated bill signals Congress may be preparing targeted changes for patients with leukemia, lymphoma, or myeloma. At introduction, however, there is no committee markup or text analysis available, so practical implications for patients, providers, and insurers remain unknown until the bill advances.